Medicon Valley Alliance and Smithers would like to welcome you to a Good Morning Meeting 14th of April 2026. Extractables and leachables remain a critical component of product quality and patient protection across pharmaceutical, biotech, and combination products. This session provides a practical overview of E&L fundamentals, recent regulatory developments, and the evolving expectations shaping […]

The modern discovery lab is no longer defined by geography alone – it is defined by how seamlessly science and execution connect across borders. Today’s most ambitious therapeutic programs – from first-in-class transcriptional degraders in resistant leukemias to rapidly advancing small-molecule or other modalities series – demand both deep biological insight and tightly integrated development […]

Medicon Valley Alliance and Fareva would like to welcome you to a Good Morning Meeting 28th of April 2026. Embarking on the journey from drug discovery to commercialization is fraught with obstacles, from unexpected issues in chemical development to challenges in drug product manufacturing. Not only is developing a new drug expensive, but an extraordinarily […]

Drug development has transformed immeasurably over the past decade. Manufacturing costs have risen, particularly for biologics (incl. CGT) and personalized medicines. In addition, the availability of comparator drug products has become less certain, making traditional packaging approaches not the most suitable for current clinical trial requirements. In response, contract manufacturing organizations (CMOs) are increasingly offering […]

Strategies & Approaches to Optimize Your Clinical Immuno-Oncology Development Precision and Immuno-Oncology drug development is being optimized through well-defined preclinical and clinical strategies focused on safety, endpoints and biomarker targets. Evolutions in the regulatory framework, a deeper understanding of cancer and re-defining key endpoints for success in Immuno-Oncology and Precision Medicine are combining to de-risk […]

Learn about the benefits of phospholipids in pharmaceutical dosage forms and innovative drug delivery systems. Natural and synthetic phospholipids are ideal multi-purpose excipients with an unrivalled safety profile in state-of-the-art pharmaceutical dosage forms. In innovative drug delivery systems phospholipids – as enabling excipients – are crucial for ensuring the efficacy of therapeutics and vaccines. Within […]

The New ICH M10 Guidelines A critical component of the regulatory decision regarding the efficacy and safety of therapeutic products is the bioanalytical concentration of therapeutic products in biological matrices. Therefore, it is imperative that the bioanalytical methods used are well characterized, validated, and documented to best support regulatory decisions. Explore the new ICH M10 […]

More so than any other core function of the biopharma industry, clinical trials have been buffeted by the prevailing winds of the pandemic. From the turbulent waves of infection causing overstretched healthcare facilities, inaccessible sites and patient availability through to the relative plain sailing of mammoth Phase III vaccine trials, COVID-19 has permanently changed the […]

– Overcoming challenges when moving from non-clinical to clinical Going from non-clinical to clinical is no easy step. That’s why we’ve gathered a few of our key experts from essential product development areas to talk about how to survive and minimize the early risks biotech companies face during the life cycle of product development. Join […]

– Breaking through the current limitations Recombinant antibodies are highly specific detection probes in research, diagnostics, and have emerged over the last two decades as the fastest growing class of therapeutic proteins. Mammalian cell lines, especially the Chinese Hamster ovary (CHO) cell line, represent the most widely used expression systems for the production of these […]

Connecting with and managing relationships with key opinion leaders (KOLs) is a crucial part of any research-based organization, as well as the surrounding ecosystem. Speaking with the right expert at the right time is invaluable. Breaking through the knowledge silos that exist within the life science industry is critical for any organization. However – finding, […]

Generalized Pairwise Comparison (GPC) is an innovative statistical method used to design and analyze clinical trials to make the best possible use of the data collected. This allows the analysis to take into account several endpoints, providing deeper insights into the net treatment benefits. Specifically, the GPC method enables you to: Assess clinical trials based […]

The pharmaceutical pipeline is gaining momentum, led by many first-time launchers. But the reality is companies spend >$200MM over three years leading up to launch, and 66% of drugs still don’t meet launch expectations. This looming risk, echoed by general industry pressures, leaves developers and investors alike looking for more advanced commercialisation options that effectively […]

Sino Biological presents: A Comprehensive Overview of the CRO Service Platform Sino Biological is dedicated in providing the scientific community with high-quality recombinant protein and antibody reagents to promote life science research and drug discovery. Several robust recombinant protein expression platforms and antibody discovery methods have been established and are available for customized contracted research […]

Starting with an overview of beyond rule of five (bRo5) drugs and the key challenges behind these drugs, in this webinar, experts will discuss how intracellular concentrations of drugs is influenced by drug-transporting proteins and metabolizing enzymes and how they are involved in delivering effective drug as well as determining toxicity and drug interactions. The […]

The success of several drugs in amorphous systems in the commercial market confirm that amorphous drug delivery system is one the efficient ways of enhancing solubility and optimizing bioavailability of poorly soluble drugs. Spray drying and hot melt extrusion are the two technologies most widely used for the preparation of amorphous solid dispersion. In addition, […]

Biopharmaceutical products in development continue to increase in complexity, which effects how companies choose to express proteins and eventually, manufacture at clinical and commercial scale. In this webinar, co-organized by Medicon Valley Alliance and Catalent, experts from Catalent Biologics and Sartorius will discuss new cell line development methodologies, including new instrumentation, which are enabling complex […]

Welcome to Medicon Valley Alliance Good Morning Meeting with IQVIA on: Value creation in a changing world: Optimising clinical trial success through a purposeful use of data and technology With over 4,000 assets in clinical development, developing medical innovation that can truly stand out has become increasingly more challenging for biotech players. Designing a compelling […]

Welcome to Medicon Valley Alliance Good Morning Meeting with Syneos Health on: Using a ‘virtual pharma model’ to attract targeted investors for biotech innovators De-risk investment, de-risk operational delivery and maximize the return on investment (ROI) for all parties How to position your organization for fundraising using a virtual pharma partner model – Using the […]

Welcome to Medicon Valley Alliance Good Morning Meeting on “Cancer immunotherapies – Preparing for a successful clinical program” with KLIFO. Recent advances in immuno-oncology have shown great promise for effective and safer treatments. Best examples are the check point inhibitors which are moving towards first line treatment in various cancer types. Currently, numerous drug modalities […]

Welcome to MVA’s Good Morning Meeting on “Biomarkers analysis challenges in Clinical Trials” with HalioDx. One of the biggest challenges in immunotherapy area is to find accurately which patients will benefit from a therapy or a combination of therapies. To help drug developers getting this information, the assessment of biomarkers through clinical research studies represent […]

Ökad samverkan över sundet, Köpenhamn & Malmö Medeon Science Park & MVA Medicon Valley Alliance bjuder in till frukostmöte. Varmt välkomna till ett frukostmöte där ni möter Medeons CEO Ulf Andersson som kommer att berätta om Medeons strategi 2016 och tankar på närmare samverkan över sundet och nya former för samarbeten med akademin. Ni får […]

Requirements for cell based assays have induced a rapid development of novel cell models. To improve the effectiveness of target research and compound development the use of patient or stem cell-derived cell models is becoming increasingly important. SIRION Biotech specializes in viral vector technology and provides sophisticated cell…

The first Good Morning Ambassador Meeting in 2013 will focus on eHealth solutions and status of telemedicine in two highly interesting countries, Japan and South Korea. Note that this event will be held in Sweden 25 February and in Denmark 26 February!

The first Good Morning Ambassador Meeting in 2013 will focus on eHealth solutions and status of telemedicine in two highly interesting countries, Japan and South Korea. Note that this event will be held in Sweden 25 February and in Denmark 26 February!

As the size and complexity of large scientific datasets increases, life sciences teams from industry and academic are using cloud computing to deliver results more quickly, at larger scale and more cost effectively. Medicon Valley Alliance in collaboration with Amazon Web Services is excited to invite you to a morning of lively discussion…

Patents are challenged during examination, opposition, and invalidity proceedings and are subjected to scrutiny during due diligence. Patent authorities and competitors try to break through the defenses. Licensees use any weakness in the patents to lower the price. Only the good patents survive. Learn from the patent experts of Høiberg how to distinguish good from […]

Patents are challenged during examination, opposition, and invalidity proceedings and are subjected to scrutiny during due diligence. Patent authorities and competitors try to break through the defenses. Licensees use any weakness in the patents to lower the price. Only the good patents survive. Learn from the patent experts of Høiberg how to distinguish good from […]

IPR rules and issues in relation to the Korean market – is patenting different in Korea, compared to Europe and USA? Yes – there are differences in legislation and practices in addition to cultural differences, which together may lead to a different outcome in the patent application process in Korea compared to Europe or America. […]